[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345161-105":59,"doc-detail-345161-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-role-of-hematological-biomarkers-as-diagnostic-tool-in-pre-cancerous-patients-review","The role of hematological biomarkers as diagnostic tool in pre-cancerous patients - Review","","A narrative review evaluates the diagnostic performance of hematological biomarkers as non-invasive indicators for early identification of precancerous states. It surveys PubMed, Scopus, and Web of Science and details how persistent inflammation in the premalignant microenvironment creates measurable systemic changes detectable by routine blood tests, including NLR, PLR, and RDW. The review compares premalignant conditions such as OPMDs, CIN, and Barrett’s esophagus using reported sensitivity, specificity, and AUC values. It also discusses limits from inflammatory overlap, and proposes multi-biomarker panels, longitudinal tracking tools, machine-learning, and molecular add-ons like cfDNA.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-role-of-hematological-biomarkers-as-diagnostic-tool-in-pre-cancerous-patients-review/345161/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-role-of-hematological-biomarkers-as-diagnostic-tool-in-pre-cancerous-patients-review/345161.png","ImageObject",300,407,{"name":92,"@type":93},"Maeve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which hematological biomarkers are highlighted for diagnosing precancerous states?","Question",{"text":112,"@type":113},"The review focuses on routine blood-test derived indices such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), red cell distribution width (RDW), and related complete blood count parameters, along with tools and additional molecular options discussed in the text.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why do single blood-test cutoffs often perform less specifically in precancerous diagnosis?",{"text":117,"@type":113},"Specificity is frequently reduced because overlapping inflammatory conditions can produce similar systemic blood changes, confounding interpretation.",{"name":119,"@type":110,"acceptedAnswer":120},"What approaches does the review recommend to improve diagnostic and risk stratification accuracy?",{"text":121,"@type":113},"It supports combining CBC elements into multi-biomarker panels, using longitudinal tracking approaches (including PIT), and integrating machine learning and molecular add-ons such as cell-free DNA (cfDNA) for improved risk assessment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345161,1790196373,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Mandefro etal. Discover Oncology (2026) 17:567 [https://doi.org/10.1007/s12672-026-04661-6](https://doi.org/10.1007/s12672-026-04661-6)  \nDiscover Oncology  \nREVIEW Open Access  \nThe role of hematological biomarkers as diagnostic tool in pre-cancerous patients  \nBefikad Mandefro 1*, Bedasa Addisu 1, Amanuel Kelem 1, Mikael Workneh 1 and Tiruneh Adane2  \n*Correspondence:  \nBefikad Mandefro[befikadmandefro@dbu.edu.et](befikadmandefro@dbu.edu.et); [befikadm@gamil.com](befikadm@gamil.com)[ ](befikadm@gamil.com)1Department of Medical Laboratory Sciences, Asrat Woldeyes Health Science Campus, Debre Berhan University, Debre Berhan, Ethiopia 2Department of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia  \nAbstract  \nThis narrative review systematically assesses the diagnostic performance of hematological biomarkers as non-invasive markers for early identification of precancerous states. Employing a comprehensive search across PubMed, Scopus, and Web of Science, it examines how persistent inflammation in the premalignant microenvironment induces detectable systemic changes through standard blood tests, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and red cell distribution width (RDW) . In contrast to prior reviews emphasizing established cancers, this synthesis focuses on premalignant conditions like oral potentially malignant disorders (OPMDs), cervical intraepithelial neoplasia (CIN), and Barrett’s esophagus, incorporating available sensitivity, specificity, and AUC data. Although these markers are highly accessible, their specificity is frequently compromised by overlapping inflammatory conditions. Thus, combining complete blood count (CBC) elements into multi-biomarker panels or using dynamic tools like the Personalized Indicator of Thrombocytosis (PIT) for serial tracking yields better prognostic accuracy than single cutoffs. The review also explores enhancements via machine learning models and molecular add-ons, such as cell-free DNA (cfDNA), for improved risk assessment. While issues like assay variability and inconsistent reference ranges persist, these blood-based biomarkers offer an affordable, adaptable strategy for surveil ling transformation risk. By tackling deployment challenges and common confounders, this work outlines a practical roadmap for leveraging routine hematological indices to boost early detection and patient outcomes in precancerous cohorts, especially in low-resource settings.  \n1 Introduction  \n1.1 Background  \nDysplasia and metaplasia offer a critical window for intervention to prevent invasive carcinoma. These premalignant states including OPMDs, CIN, and Barrett’s esophagus exhibit distinct pro-inflammatory shifts that precede overt malignancy. While biopsy remains the gold standard, its invasiveness and susceptibility to sampling error underscore the need for non-invasive alternatives. Currently, the systemic inflammatory response of the premalignant niche remains an underutilized diagnostic resource. This review evaluates the performance of accessible hematological biomarkers, shifting  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons","cbCaiqAyLrK4SbYx","https://ap.wps.com/l/cbCaiqAyLrK4SbYx","pdf",818954,14,"English","# Abstract\n# 1 Introduction\n## 1.1 Background","[{\"question\":\"Which hematological biomarkers are highlighted for diagnosing precancerous states?\",\"answer\":\"The review focuses on routine blood-test derived indices such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), red cell distribution width (RDW), and related complete blood count parameters, along with tools and additional molecular options discussed in the text.\"},{\"question\":\"Why do single blood-test cutoffs often perform less specifically in precancerous diagnosis?\",\"answer\":\"Specificity is frequently reduced because overlapping inflammatory conditions can produce similar systemic blood changes, confounding interpretation.\"},{\"question\":\"What approaches does the review recommend to improve diagnostic and risk stratification accuracy?\",\"answer\":\"It supports combining CBC elements into multi-biomarker panels, using longitudinal tracking approaches (including PIT), and integrating machine learning and molecular add-ons such as cell-free DNA (cfDNA) for improved risk assessment.\"}]","The role of hematological biomarkers as diagnostic tool in pre-cancerous patients - Review | PDF",1790056683,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ab37ae817815261e8835b88410c2bacb.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb061f933fd66c787be1e3334ffa23e1.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41d89f3fabc83f1a38a402d46653a77a.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3afd67eabbe262b94eb8e37fd991e247.webp",980,1306]